Rosen Law Firm has announced an investigation into Anavex Life Sciences Corp. for potentially issuing materially misleading business information to shareholders. The investigation follows Anavex's May 2026 disclosure that its CEO, Dr. Christopher Missling, was terminated for cause due to conduct inconsistent with company policy. Investors who purchased Anavex securities may join a class action to seek compensation without upfront fees. Rosen Law Firm, known for its expertise in securities class actions, is preparing to represent affected shareholders in recovering losses.
Anavex Life Sciences Corp. is the subject of a securities class action investigation. For readers following health-sector stocks, here is Pluang's market snapshot as of Sep 22, 2026 03:42 WIB: Of 94 priced US health stocks, 56 rose and 38 fell. Notable movers include BNGO at USD 1.85 with a 6.94% increase and 90% sell order activity, SMMT at USD 16.90 down 5.32% with 100% buy order activity, and HIMS at USD 29.28 up 4.61% with 88% sell order activity. Typical hold times vary from 18 to 49 days on Pluang.
Two directors of Equitable Holdings sold shares recently, with Bertram L. Scott selling 2,780 shares and Craig C. MacKay selling 2,000 shares. Meanwhile, institutional investors showed mixed activity: Engineers Gate Manager LP drastically cut its hol...
Shares of Greenland-linked mining companies surged following a new U.S.-Denmark-Greenland security agreement that boosted investor interest in Greenland's mineral resources. Greenland Mines Ltd. jumped over 229%, while Critical Metals Corp. rose near...
Biotech stocks and leveraged ETFs were the biggest losers in the market, with Cue Biopharma dropping 23.7% despite positive Phase 2 clinical results. Leveraged ETFs tied to AMD, Strategy, and Novo Nordisk also saw sharp declines due to their daily-re...
Priority Technology Holdings is being taken private in a $1.6 billion deal led by its Chairman and CEO, Thomas Priore. The acquisition price is $8.05 per share, matching the analyst price target set by Lake Street, which downgraded the stock to 'Hold...
General Mills is set to report its Q3 2026 earnings with an expected 16.3% decline in earnings per share to $0.72 and revenue forecast around $4.35 billion, down from last year. Despite these declines, the company reaffirmed its full-year adjusted EP...
